Small (4-12 kDa) binding proteins have the potential to bridge the gap between monoclonal antibodies and small molecule drugs 1-3 , with advantages of stability and amenability to chemical synthesis over monoclonal antibodies, and of selectivity and designability over small molecules. Directed evolution, starting from naturally occurring small protein scaffolds, has previously been used to generate new binding proteins 4 . While powerful, such approaches have limitations: they cannot modify the overall shape of the starting scaffold protein(s), they can sample only a very small fraction of sequence space, and naturally occurring disulfide mini-proteins can be difficult to express. Computational protein design has the potential to overcome these limitations by efficiently sampling both shape and sequence space on a much larger scale, and by generating readily producible proteins, as recently demonstrated by the design of stapled mini-protein scaffolds with a wide range of shapes 5 . Despite this potential, the high cost of synthesizing genes for each designed protein has, until recently 6 , limited testing to small numbers (tens) of designs for any one application, which is too few to systematically explore the determinants of protein binding and folding and provide feedback to improve the computational model 7,8 . Here, we describe an integrated computational and experimental approach that enables the rapid design and testing of tens of thousands of de novo mini-protein binders. Our approach exploits advances in both DNA manufacturing and protein design that have led to a fortunate convergence between the upper limit of the size of oligonucleotides (230 bp) that can be synthesized as pools of 10,000 or larger 9,10 , and the lower limit of the size of genetically encodable computationally designed proteins (roughly 40 amino acids). To generate binders for a given target, we used Rosetta 11 to design thousands of protein scaffolds with varying shapes, dock these onto the target, optimize the residues at the interface for high-affinity binding, and identify, from the resulting pool of hundreds of thousands of designs, approximately 10,000 with high predicted stability and affinity. This large pool of computational designs, together with controls probing aspects of the design procedure, was then experimentally evaluated by encoding each individual sequence in a single oligonucleotide, manufacturing the oligonucleotides in parallel, sorting yeast libraries displaying the designs labelled with fluorescent targets, and using deep sequencing to identify the designs most enriched for binding (Fig. 1) .
Small (4-12 kDa) binding proteins have the potential to bridge the gap between monoclonal antibodies and small molecule drugs 1-3 , with advantages of stability and amenability to chemical synthesis over monoclonal antibodies, and of selectivity and designability over small molecules. Directed evolution, starting from naturally occurring small protein scaffolds, has previously been used to generate new binding proteins 4 . While powerful, such approaches have limitations: they cannot modify the overall shape of the starting scaffold protein(s), they can sample only a very small fraction of sequence space, and naturally occurring disulfide mini-proteins can be difficult to express. Computational protein design has the potential to overcome these limitations by efficiently sampling both shape and sequence space on a much larger scale, and by generating readily producible proteins, as recently demonstrated by the design of stapled mini-protein scaffolds with a wide range of shapes 5 . Despite this potential, the high cost of synthesizing genes for each designed protein has, until recently 6 , limited testing to small numbers (tens) of designs for any one application, which is too few to systematically explore the determinants of protein binding and folding and provide feedback to improve the computational model 7, 8 . Here, we describe an integrated computational and experimental approach that enables the rapid design and testing of tens of thousands of de novo mini-protein binders. Our approach exploits advances in both DNA manufacturing and protein design that have led to a fortunate convergence between the upper limit of the size of oligonucleotides (230 bp) that can be synthesized as pools of 10,000 or larger 9, 10 , and the lower limit of the size of genetically encodable computationally designed proteins (roughly 40 amino acids). To generate binders for a given target, we used Rosetta 11 to design thousands of protein scaffolds with varying shapes, dock these onto the target, optimize the residues at the interface for high-affinity binding, and identify, from the resulting pool of hundreds of thousands of designs, approximately 10,000 with high predicted stability and affinity. This large pool of computational designs, together with controls probing aspects of the design procedure, was then experimentally evaluated by encoding each individual sequence in a single oligonucleotide, manufacturing the oligonucleotides in parallel, sorting yeast libraries displaying the designs labelled with fluorescent targets, and using deep sequencing to identify the designs most enriched for binding ( Fig. 1 ).
High-throughput computational design
As targets, we selected Influenza A H1 haemagglutinin (HA), as this virus remains a serious public health concern 12 , and botulinum neurotoxin B (BoNT/B), which causes the acute neuroparalytic syndrome of botulism and is one of the most lethal natural toxins known (with a lethal dose of approximately 1 ng per kg) 13 . We generated virtual scaffold libraries with over 4,000 backbone geometries in five different topologies: HHH, EHEE, HEE, EEHE, and HEEH (where H indicates an α -helix and E a β -strand) with or without 5,6 diverse disulfide connectivities (Fig. 1a) . To design binding interfaces, we superimposed helical segments of the scaffolds on interface helices in previously solved HA and BoNT/B complexes (the previously designed HA binders HB36.6 and HB80.4 with hotspot residues from these helices (Extended Data Fig. 1 ) and designed the remainder of the residues to maximize binding affinity and monomer stability using Rosetta combinatorial sequence optimization ( Supplementary Fig. 1 ). The designs interact with the targets in a myriad of ways (Fig. 1b) , with a wide range of buried surface areas at the interface (Fig. 1c) resulting from variations in the Rosetta designed interactions outside the hotspot residues. As HA and BoNT differ in shape (the HA epitope is more concave and the BoNT epitope is flatter), the design protocol favoured different topologies in the two cases (α -β for HA and all α for BoNT).
For experimental characterization, we selected 7,276 designs against HA and 3,406 designs against BoNT (see Methods). To probe contributions to folding and binding, we also included a variety of control sequences in which the amino acids outside the helical interface motif were randomly permuted, the core residues were randomly permuted, all the core residues were mutated to valine, the loop residues were mutated to Gly-Ser, or the designed binding sites were omitted. Oligo pools encoding all of the design and control sequences (16,968 in total) were synthesized, amplified, and co-transformed into yeast, along with a linearized yeast display vector (Fig. 1d) . The resulting yeast libraries, displaying the 16,968 proteins, were incubated with a range of concentrations of fluorescently labelled target, in some cases after protease treatment to remove poorly folded designs. Cells displaying designs that bound the target were retrieved by fluorescence-activated cell sorting (FACS, Fig. 1e ). The frequency of each design and control sequence in each pool was determined by deep sequencing the sorted cell populations, and the sequences were categorized on the basis of the sorting condition in which they were most enriched (Extended Data Fig. 2 ).
Deep sequencing of the initial yeast-transformed pools showed near complete representation of full-length genes; the HA pool contained 11,002 of the 11,657 sequences ordered (94.4%) and the BoNT pool contained 5,306 of the 5,311 sequences ordered (99.9%). Sorting the pools under conditions of increasing stringency (decreasing concentration of target) sharply reduced the number of distinct sequences recovered (Fig. 2) . For the BoNT pool, after sorting at target concentrations of 100, 10 and 1 nM, the enriched binder populations contained 2,685, 987 and 355 distinct sequences, respectively; a final higher stringency screen that involved incubating with protease before assaying for binding (to favour highly stable designs) reduced the population to 57 distinct sequences. At 1 nM of BoNT with no protease treatment, 7.8% of the designed sequences, 5.1% of the scrambled core variants, 1.4% of the valine core variants and none of the Gly-Ser loop variants were enriched. For the HA pool, after sorting against HA (from influenza strain A/PuertoRico/8/1934 (PR8)) concentrations of 1,000, 100 and 10 nM, the enriched populations contained 115, 41 and 29 distinct sequences, respectively. For both targets, the population fraction of the computationally designed mini-proteins increased over that of the scrambled control sequences as selection stringency increased; computational design considerably increased the probability of binding the target with high affinity. The simplest explanation for this is that a substantial fraction of the proteins fold into the designed structures. b, For each non-clashing dock of each scaffold onto each target, the monomer and interaction energies were optimized with Rosetta sequence design. Representative models are shown at the left of each column. Right columns show a top view of the target with the hotspot interaction areas coloured as above and new contact areas generated by Rosetta sequence design coloured yellow; the total number of unique designs generated is indicated at the bottom. c, Designed contacts substantially increase the interface buried surface area of the designs beyond the starting hotspot residues. d, Genes encoding 16,968 mini-protein designs, including 6,286 controls, were synthesized using DNA oligo pool synthesis (see Methods). e, The oligo pools were recombined into yeast display vectors and transformed into yeast (see Methods), and binding of the designs HA or BoNT at different concentrations was assessed by FACS. For each sorting condition, enriched designs were identified by comparing the frequencies in the original and sorted populations using deep sequencing. These data were used to guide improvement of the computational design model, and the entire design, synthesis and testing cycle was iterated.
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The design population included 3,264 BoNT designs with single disulfides and 3,594 HA designs with multiple disulfides in geometrically allowed positions. For both targets, designs containing disulfides had similar success rates to those in which disulfides were absent (26.2% versus 25.5% for BoNT and 0.5% versus 0.8% for HA), consistent with a late and non-instructive role for disulfides in protein folding. However, when the design libraries were treated with trypsin before binding selection, only disulfide-stabilized designs were recovered; although they do not guide protein folding, the disulfides clearly confer stability against proteolysis (Extended Data Table 1 ).
Assessment of the computational model
The measured binding activity of a design reflects both the extent to which the protein is folded and the binding affinity of its folded state to the target. In general, sequences with binding activity had lower computed folding energies and binding energies (Fig. 3a) : this may be the largest-scale confirmation to date of the ability of a computational model to recapitulate protein-protein interactions. The second-order features most strongly associated with binding were local sequencestructure compatibility and the numbers of contacts across the interface (Fig. 3b) . On the basis of these results, we updated the design protocol (see Methods) and generated 11,420 new HA designs for a second round of experimental testing (Fig. 3c) , in which the success rate increased from 1.4% to 3.1% (producing 342 new HA binders). The improvement was particularly marked in the subset of HB2 seeded designs, improving the success rate almost tenfold from 0.23% to 1.9%. Iterations of this design-build-test cycle should reveal additional contributions that are missing in the current model, which can then be captured in the energy function and design protocol.
The large dataset provides an opportunity to determine whether extensive molecular dynamics simulations in explicit solvent can reproducibly distinguish binding and non-binding designs. We simulated 143 randomly selected non-binders and 146 binders that were evenly split between HA and BoNT, for a total simulation time of 108 μ s (see Methods). Although there was little correlation with the overall structural deviation from the design model, the interface hotspot residues fluctuated to a lesser extent in the binding designs than in the non-binding designs (Fig. 3d) , suggesting that binding site preorganization is important for binding and that molecular dynamics simu lations capture this property reasonably well (Extended Data  Fig. 3) .
To investigate the sequence dependence of folding and function in more detail, we generated and screened single-site saturation mutagenesis (SSM) libraries for six HA and two BoNT designs, with every position mutated to every amino acid, one at a time (a total of 6,126 mutants). Substitutions at the binding interface and in the protein core were more disruptive than substitutions at surface positions, and almost all the cysteines were highly conserved in designs containing disulfides (Fig. 3e-f and Supplementary Fig. 3a-h ). Rosetta designed interactions outside the hotspot regions were found to make important contributions to binding ( Supplementary Fig. 3a-h) ; mutations of the nonhotspot HB1.6928.2 residues Ala11, Trp19, and Tyr24 (see Fig. 4a ), for example, greatly decreased binding affinity. The effects of each mutation on both binding energy and monomer stability were estimated using Rosetta design calculations, and a reasonable correlation was found between the predicted and experimentally determined susceptibility of positions to mutation for three of the six designs for HB1 and both of the two BoNT designs (Supplementary Fig. 2 ). Finally, the SSM datasets were used to guide generation of higher affinity HA and BoNT binders (see Extended Data Table 2 and Methods).
Individual characterization of designed binders
Eight BoNT and six HA binders, a mix of affinity-matured and original designs, were chemically synthesized or expressed in Escherichia coli, purified, and characterized in solution (Extended Data Table 2 ). All 14 designs had circular dichroism spectra consistent with the design models, and melting temperatures greater than 70 °C (Extended Data  Fig. 4a ). Designs containing disulfides did not unfold at 95 °C and were Table 2 ); the total number of surviving designs is indicated by the numbers at the far right. For example, after incubation of the HA mini-protein population with 100 nM HA, FACS and deep sequencing, the population fractions of both non-disulfide (blue) and disulfide (yellow) designs doubled compared to the starting population, while that of the non-disulfide scrambles decreased approximately fivefold and the disulfide scrambles completely disappeared.
resistant to trypsin (Extended Data Fig. 5) ; reduction of the disulfides with the reducing agent tris(2-carboxyethyl)phosphine (TCEP) considerably decreased their stability (Extended Data Fig. 4b,c) . The BoNT binders bound to H C B with affinities ranging from 1 to 20 nM by biolayer interferometry, and also bound the serotype G of botulinum neurotoxin (BoNT/G) (see Methods and Supplementary Fig. 4 ). The HA binders bound to HA proteins from two H1N1 influenza strains, PR8 and A/California/04/2009 (CA09); the three affinitymatured binders had affinities against CA09 below 10 nM (Extended Data Table 2 ). We succeeded in solving crystal structures of both HA and BoNT H C B binders (HB1.6928.2.3 and Bot.671.2.1, respectively) in complex with their targets. In both cases the complexes were in excellent agreement with the computational design models Tables 1 and 2) .
To compare the ability of the designs to survive high temperature exposure with that of antibodies, we incubated HB1.6928.2.3, Bot.671.2.1, and the haemagglutinin-targeting antibody mAb FI6v3 at 80 °C for various times before performing binding assays to their respective targets. The mini-protein binders showed no detectable loss of binding after 1 hour at high temperature, while FI6v3 binding activity was reduced by approximately 74% (Fig. 4c) . These results suggest that therapeutics relying on small designed proteins could bypass the requirement for cold chain management for monoclonal antibodies.
In vitro assays were carried out for BoNT and influenza. HB1.6928.2.3, an affinity-matured, disulfide-containing design, strongly neutralized PR8 and CA09 influenza viruses after 48 hours in culture, with a half-maximal effective concentration (EC 50 ) value for Cal09 (CA09) more than 100-fold lower than the broadly neutralizing antibody FI6v3 18 , or the previously designed HB36.6 14 , on the basis of mass ( Fig. 4d ; the EC 50 is similar to the antibody on a molar basis). Paralleling this, Bot.671.2 protected rat cortical neurons against the entry of the BoNT/B toxin and against cleavage of the vesicle-associated membrane protein 2 (VAMP2; the intracellular target of BoNT/B) ( Fig. 4e) at lower concentrations than Syt-II (the BoNT/B receptor), which contains the same hotspot residues (Extended Data Fig. 7 ). The increase in protection is likely to reflect both the reduction in conformational entropy of the binding motif and the additional designed interface contacts.
HB1.6928.2.3 protected mice from influenza both pre-and postexposure. Intranasal administration of HB1.6928.2.3 twenty-four hours before lethal challenge with CA09 influenza resulted in 100% survival BoNT (bottom) show that designs that bind target (blue) have better local sequence-structure compatibility, quantified by the Rosetta side-chain probability score -p_aa_pp, and higher interface atom counts than non-binding designs (red). Design success rate (dark green) is shown with 1σ confidence interval (light green). c, Inset: Receiver-operator characteristic curve for discriminating first generation HA binders using a five-factor logistic regression. A second generation of HA binder design incorporating filtering on these five features (see Methods) had an increased success rate (y-axis); the numbers of successes are indicated above the bars. d, Interface residue fluctuations in molecular dynamics simulations are smaller for binding designs than non-binders (see Methods and Extended Data Fig. 3 ). e, f, Left, design models of Bot.671.2 (e) and HB1.6928.2.3 (f) bound to their targets, coloured by the mean change in binding at each position in the comprehensive mutagenesis pools; conserved residues (blue) are shown as sticks, non-conserved positions in red. Right, the experimentally observed mean changes in binding at each position (y-axis) correlate with those computed from the structures (x-axis) (Pearson cross-correlation test: e, r = 0.76; f, r = 0.64). , which is 100-fold lower on the basis of mass than the dose of FI6v3 required for equivalent protection ( Fig. 5a and Supplementary Fig. 6 ). Therapeutic administration of a single 3 mg kg −1 dose of HB1.6928.2.3 twenty-four hours after virus challenge resulted in 100% survival and little (less than 10%) weight loss (Fig. 5b) ; the same dose administered 72 hours after challenge imparted complete protection and 100% survival (Fig. 5b) . Intravenous administration of HB1.6928.2.3, however, resulted in little protection, indicating that (as with the on-market drug Zanamivir 19 ) intranasal administration is likely to be the optimal delivery route for these mini-proteins.
Three sequential doses of the mini-proteins, administered by intranasal or intravenous delivery every two weeks, induced little or no antibody response (Fig. 5c) : the low levels of antibody detected were comparable to those induced by mouse IgG (negative control), and substantially less than levels induced by human IgG (positive control). Intranasal administration of the influenza mini-protein binders 24 hours prior to viral challenge still achieved 100% prophylactic efficacy even in mice that had previously received four repeated intranasal or intravenous doses of the mini-protein over a space of twelve weeks (Fig. 5d) , indicating that any immune response and clearance is minimal and not sufficient to interfere with antiviral potency. The low immunogenicity is likely to be a consequence of the very small size and hyperstability of the mini-proteins, and suggests that the binders could be used for prophylactic protection against influenza over an extended period of time. To our knowledge, this is the first investigation of the immunogenicity of de novo designed proteins.
Conclusions
The high throughput of our pipeline from computational design to experimental testing enables the characterization of computationally designed binding proteins on a scale that is orders of magnitude greater than those of previous studies, providing insights into the contributions to folding and binding on thousands of test cases simultaneously. For example, our observation that substituting designed loop sequences with generic Gly-Ser linkers reduced binding fitness to a greater degree than did substituting the designed core residues with valine (or scrambling their order) suggests that loops may play an underappreciated, instructive role in the folding of proteins of this size. Different topologies were found to be optimal for the BoNT and HA interfaces, supporting the hypothesis that no single protein topology or shape is the best fit for all interfaces. The massively parallel design process succeeded in generating folded high-affinity binding proteins despite uncertainties in designing 40-residue proteins with multiple hydrophobic residues (which potentially complicate folding) on their surfaces. Iteration between data-driven model improvement and experimental testing is likely to improve both the computational design methodology and our understanding of the determinants of folding and binding: the limited number of native protein structures from which much of our current knowledge is derived is dwarfed by the nearly unlimited number of de novo proteins that can be designed and tested using our approach.
De novo protein design has the potential to generate pharmaceutically superior molecules that combine the specificity of antibodies with the high stability and manufacturability of small molecules. Designed protein binders have previously been produced by re-engineering naturally occurring proteins; although these achieve some of the above goals (such as accurate site-specific binding), they are not more robust than antibodies. The de novo designed binders described here exhibit much greater stability to incubation at elevated temperatures and better neutralization than comparable antibodies and natural protein derivatives, have approxi mately 1/30th of the molecular weight, and are readily chemically synthesizable, which enables the introduction of a wide variety of chemical functionality. Probably as a result of their small size and very high stability, they elicit little immune response even without explicit negative design 20 , and the best of the HA designs provides prophylactic and therapeutic protection against influenza infection in vivo with a potency rivalling or surpassing that of antibodies. Unlike antibodies, the mini-proteins do not contain the effector recruiting IgG Fc region; our results show the latter is not required for potent protection against influenza, and therapeutics which lack the Fc could avoid issues of antibody enhanced infectivity. More generally, hyperstable designed miniproteins show promise for both therapeutic and diagnostic applications.
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MethOdS
Unless stated otherwise, the experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Mini-protein binders design. Mini-protein design began by defining a variety of mixed α -β and α -only scaffold topologies using the RosettaRemodel 'blueprint' format 21 with the requirement of at least one 10-14-residue helix. The blueprints were used to generate backbones using the Rosetta Monte Carlo-based fragment assembly protocol 22, 23 . Between one and three disulfides were added to a subset of these backbones at geometrically allowed positions. Sequence design was performed using the FastDesign protocol with layer control active, alternating between side-chain rotamer optimization and gradient-descent-based energy minimization. For each topology, over 10,000 structures were generated and filtered on overall energy per residue and score terms related to backbone quality, compactness and disulfide quality (see Supplementary Appendix) .
To match the mini-protein scaffolds with the desired target helix-binding motifs, we used the Rosetta MotifGraft Mover 7, 24 . The inputs were composed of: (1) HB36, HB80 or Syt-II helical binding motifs (Protein Databank (PDB) IDs: 3R2X, 4EEF and 2NM1, respectively); (2) the context target protein (influenza HA or BoNT H C B); and (3) the above described library of de novo mini-protein scaffolds. Matching parameters were set to perform full backbone alignment of the input motif, with a maximum backbone r.m.s.d. = 1 Å, endpoints r.m.s.d. = 1 Å, clash_score_cutoff = 5 and enabling revert_graft_to_native_sequence. In the case of BoNT/B's Syt-II binding domain, the hotspots were defined as: Met1, Phe2, Leu5, Lys6, Lys8, Phe9, Phe10, Glu12, Ile13 (see Extended Data Fig. 1 ). For the influenza HA HB80.4 (HB1) binding domain, the hotspots were defined as: Phe1, Ile5, Ile9, Phe13. For the influenza HA HB36.6 (HB2) binding domain, the hotspots were defined as: Phe1, Met5, Trp9, Phe13. Following MotifGraft, we performed Rosetta's sequence repack of interface neighbouring residues (except hotspots), Cartesian minimization and filtering using the scoring function Talaris2013 or Talaris2014.
After the first round of HA design and testing, the Kolmogorov-Smirnov two-sample test was used to determine P values for the null hypothesis that the computational metrics of the binding versus non-binding designs were drawn from the same underlying distribution. Using the metrics that correlated strongly with success (such as those shown Fig. 3b) , a second round of HA design was performed which incorporated more stringent filtering on a broader range of metrics. The metrics used to select the first round of HA designs were delta G of binding (ddg filter), shape complementarity (sc), and interface buried surface area (SASA). The additional metrics used to select the second generation HA designs and shown to be highly predictive of round one success in the logistic regression model (Fig. 3c  inset) were average degree (degree), side-chain probability given phi-psi (p_aa_pp), per cent core by side-chain neighbours, phi-psi probability given side-chain (rama) and more stringent shape complementarity. Design models are available online (https://zenodo.org, http://dx.doi.org/10.5281/zenodo.838815). Software analysis. All amino acid sequences were reverse translated and codon optimized for yeast using DNAworks 2.0 25 . Sequence identity calculations were performed with a subset of designs using PRALINE 26 after PSI-BLAST global alignment. Sequencing pairing after Illumina deep sequencing was performed using PEAR 27 . Plots and visualizations were created using Seaborn statistical visualization tools 28 , Python (Python Software Foundation) and Python's scikitlearn (INRIA). Gene pools. Oligo library pools ordered from either CustomArray or Agilent with all genes 3′ and 5′ flanked with common 20-bp adaptor segments to allow amplification. We obtained conventional oligonucleotides (PCR primers and sequencing primers) from Integrated DNA Technologies. The raw oligonucleotide pools were amplified with Kapa HiFi Hotstart Ready Mix (Kapa Biosystems) using extension primers to add pETCON yeast homologous recombination segments (40 bp) to each end. All amplifications were performed using real-time PCR on a MiniOpticon (Bio-Rad) for between 9 and 20 cycles. Quantitative PCR amplification was critical as over-amplification of gene pools resulted in low transformation efficiency. Amplified pools were size-selected on a 2% agarose gel and cleaned (Qiagen QIAquick Gel Extraction Kit). A second round of quantitative PCR amplification was performed with the same primers on the size-selected pools to generate 2-4μ g of DNA. Yeast EBY100 cells were transformed with library DNA and linearized pETCON plasmid 29 using an established protocol 30 . After transformation (minimum 1 × 10 7 transformants), cells were grown overnight in SDCAA medium in 30-ml cultures at 30 °C, passaged once, and stored in 20 mM HEPES 150 mM NaCl pH 7.5, 20% (w/v) glycerol in 1 × 10 7 -cell aliquots at − 80 °C. Yeast display and deep sequencing. Cell aliquots were thawed on ice, centrifuged at 13,000 r.p.m. for 30 s, resuspended in 1 × 10 7 cells per ml of C-Trp-Ura medium and grown at 30 °C for 16 h. Cells were then centrifuged at 13,000 r.p.m. for 1 min and resuspended at 1 × 10 7 cells per ml SGCAA medium and induced at 30 °C for 16-24 h. Cells were labelled with either biotinylated BoNT H C B, PR8 haemagglutinin, or CA09 haemagglutinin, washed, secondarily labelled with streptavidinphycoerythrin (SAPE, Invitrogen) and anti-c-Myc fluorescein isothiocyanate (FITC, Miltenyi Biotech), and sorted by fluorescent gates under various stringency conditions using a Sony SH800. HA target proteins were produced as previously described 16 . Cells were recovered overnight at 2.5 × 10 5 collected cells per ml SDCAA medium, whereupon at least 1 × 10 7 cells were spun down at 13,000 r.p.m. for 1 min and stored as cell pellets at − 80 °C before library preparation for deep sequencing. Between 1 × 10 7 and 4 × 10 7 yeast cells were barcoded and prepared for deep sequencing for each library as previously described 15 . Enhanced score files including all sequences ordered, computational metrics, and enrichments are available online (https://zenodo.org, http://dx.doi.org/10.5281/zenodo.838815). SSM and affinity maturation. SSM libraries for eight designs (Supplementary Figs 2  and 3a-h) were constructed from Agilent gene pools, and yeast display selections performed as described above, using target protein concentrations of 1,000 nM, 100 nM, 10 nM and 1 nM for HA, and 100 nM, 10 nM, 1 nM, 1nM + (trypsin at 18.5 μg ml −1 ) for BoNT H C B. Upon deep sequencing, the five most beneficial mutations at nine positions in each of the HA designs predicted to result in higher affinity were combined into high-diversity libraries (< 1 × 10 7 ) using wobble bases as guided by SwiftLib 31 . A DNA library for each design was constructed from assembly PCR using Ultramer oligonucleotides (Integrated DNA Technology) to encode the variable region. Primers and sequences are listed in Supplementary  Table 3 . These libraries went through three increasing stringency sorts: rd1 100 nM, rd2 10 nM, and rd3 1 nM against CA09. Promising constructs were identified through Sanger sequencing of a subset of the final rd3 pool. Versions of the BoNT designs were directly generated from SSMs by incorporating the best beneficial mutations to create high-affinity variants; no selections were used. Mini-protein expression and peptide synthesis. Genes encoding the designed protein sequences were synthesized and cloned into pET-28b(+ ) E. coli plasmid expression vectors (GenScript, N-terminal 6 × His tag and thrombin cleavage site). Plasmids were then transformed into chemically competent E. coli Lemo21 cells (NEB). Protein expression was then induced with 1 mM of isopropyl β -d-thiogalactopyranoside (IPTG) at 18 °C. After overnight expression, cells were collected and purified by nickel affinity followed by size-exclusion fast protein liquid chromatography (Superdex 75 10/300 GL, GE Healthcare) and mass spectrum verification of the molecular weight of the species in solution (Thermo Scientific). Peptide sequences were synthesized from commercial vendors Biomatik or CS Bio in 50 mg quantities with 70% purity requirements. Sequences containing cysteines underwent standard natural oxidation performed by vendor. Circular dichroism. Far-ultraviolet circular dichroism measurements were carried out with an AVIV spectrometer model 420 in PBS buffer (pH 7.4) in a 1 mm path-length cuvette with protein concentration of approximately 0.25 mg ml Biolayer Interferometry. Binding data were collected in an Octet RED96 (ForteBio) and processed using the instrument's integrated software using a 1:1 binding model. For BotNT/B binding proteins, the target BoNT heavy chain protein domains (H C B or H C G) were covalently linked to amine-reactive sensors (ARG2, ForteBio) at 5 μ g ml −1 in acetate buffer for 300 s, while the binding proteins to assay were diluted from a concentrated stock into binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20, 0.5% non-fat dry milk). For influenza binding proteins, streptavidin-coated biosensors were dipped in wells containing biotinylated HA proteins (100 nM) in binding buffer for immobilization for 300 s, while the binding proteins to assay were diluted from a concentrated stock into binding buffer (1 × phosphate buffered saline (PBS) pH 7.4, 0.01% BSA, 0.002% Tween 20). After baseline measurement in binding buffer alone, the binding kinetics were monitored by dipping the biosensors in wells containing defined concentrations of the designed protein (association) and then dipping the sensors back into baseline wells (dissociation). For heat-time courses, the proteins were incubated for defined times at a concentration of 160 nM in PBS buffer (150 nM NaCl, pH = 7.4) and then diluted to 8 nM in the final buffer and assayed as described above. BoNT/B (H C B) co-crystal structures. H C B was expressed and purified as previously described 32 . For X-ray crystallography, the H C B-Bot.671.2 complex was prepared by mixing H C B with the binder at a molar ratio of 1:1.5 and the complex was further purified by a Superdex 200 SEC (GE Healthcare) in a buffer containing 150 mM NaCl, 10 mM Hepes pH 7.0, 1 mM TCEP. Initial crystallization screens were carried out using a Gryphon crystallization robot (Art Robbins Instrument) and commercial high-throughput crystallization screen kits from Hampton Research and Qiagen. After extensive manual optimization, the best crystals were grown by sitting-drop vapour diffusion at 18 °C. The protein (5 mg ml −1 ) was mixed in 2:1 ratio with a reservoir solution containing 100 mM Tris pH 8.0, 25% polyethylene glycol (PEG) 400. The crystals were cryoprotected in the original mother liquor and flash-cooled in liquid nitrogen. X-ray diffraction data were collected at 100 K at beamline 24-ID-E, Advanced Photon Source (APS). The data were processed using XDS 32, 33 . The structure was determined by molecular replacement software Phaser using the structure of the H C B (PDB code: 2NM1) as the search model 32 . The manual model building and refinement were performed in COOT 34 and PHENIX 35 in an iterative manner. The refinement progress was monitored with the R free value 36 using a 5% randomly selected test set. The structures were validated through the MolProbity web server 36, 37 and showed excellent stereochemistry. Data collection and structural refinement statistics are listed in Supplementary ) were used to neutralize the system. Integration time step was 2 ps and LINCS 44 was applied to constrain all the bonds. Long-range electrostatics (greater than 12 Å) were treated with the particle-mesh Ewald method 45 . Van der Waals interactions were smoothly switched off between 10 Å and 12 Å. After minimization (10,000 steps), the system was position restrained for 200 ps in an NVT ensemble (only heavy atoms, restraint = 10 kJ per mol × Å −2 , T = 310 K), followed by 500 ps of NPT (T = 310 K, restraint = 10 kJ per mol × Å −2 , 1 bar) using Berendsen thermostat and barostat 46 . For each protein, we then performed five independent NPT production simulations (T = 310K, 1 bar) with 500 ps of initial temperature annealing (T 0 = 50, T final = 310 K) using V-rescale thermostat 47 and Parrinello-Rahman Barostat 48 . Each production simulation was in the length of 100 ns for BoNT and 50 ns for influenza binders (see Supplementary Information). Snapshots were recorded every 50 ps, and all of them were used for subsequent data analysis (Extended Data Fig. 3) . Influenza neutralization assays. One hundred TCID 50 units of virus and half-log dilutions of binders were incubated in quadruplicate at 37 °C for two hours in 200 μ l neutralization assay medium ('NAM': medium 199, 0.3% BSA, 10 mM HEPES,1 mM CaCl 2 , penicillin-streptomycin). Ninety-six-well plates with confluent monolayers of Madin-Darby canine kidney epithelial cells (ATCC) were washed twice with PBS followed by addition of 50 μ l of 5 μ g ml −1 TPCK-trypsin in NAM and the virus/binder neutralization mix. Plates were incubated for 48 h and virus detected by combining 50 μ l each of assay supernatants and 0.5% turkey red blood cells (TRBC). Virus-positive wells that haemagglutinated the TRBC were identified, and the EC 50 was calculated using Reed-Muench method. Botulinum neurotoxin neutralization assays. All procedures were conducted in accordance with the guidelines approved by the Institute Animal Care and Use Committee (IACUC) at Boston Children's Hospital (#3030). Timed-pregnant rats (Sprague Dawley strain, purchased from Charles River) were euthanized and primary rat cortical neurons were prepared from E18-19 embryos using a papain dissociation kit (Worthington Biochemical). For immunoblot analyses, neurons were exposed to BoNT/B (20 nM) or BoNT/A (10 nM) with GST-Syt-II or Bot.671.2 for 10 min in high [K + ] buffer. Subsequently, the neurons were washed and incubated in culture medium for 10 h (BoNT/B) or 6 h (BoNT/A). Cells were then lysed (lysis buffer: PBS, 1% Triton X-100, 0.05% sodium dodecyl sulfate (SDS), plus protease inhibitor cocktail (Roche)). Lysates were centrifuged (4 °C) for 5 min at maximum speed using a microcentrifuge. The supernatants were collected for immunoblot analysis against BoNT/A, BoNT/B or actin. For immunocytochemistry, the neurons were seeded on cover glass in 24-well plates. The cells were then exposed to 20 nM BoNT/B for 10 min (middle panel, positive control), or with 20 nM BoNT/B and 600 nM Bot.671.2 for 10 min. Cells were washed with PBS and fixed with 4% paraformaldehyde for 20 min. The cells were then blocked with PBS containing 10% goat serum for 45 min and exposed to primary antibody (rabbit anti-BoNT/B antibody) for 1 h and secondary antibody (Alexa-488) for 1 h. The coverslips were then mounted on a slide and images collected using a fluorescence microscope. See Extended Data Fig. 7 . In vivo immunogenicity and influenza challenge. Animal studies were approved by the University of Washington Institutional Animal Care and Use Committee. BALB/c mice (female, 6-8 weeks old, n = 5-10 per group) were randomly separated into groups, anaesthetized and then were dosed either intranasally or intravenously with PBS (negative control), the antibody FI6 (SFFV-FI6v3 IgG, Molecular design & Therapeutics) or mini-protein binders (HB1.6928.2.3 or HB36.6). Between 24 and 96 h after being dosed (see Fig. 5 ), the mice were anaesthetized with 2.5% isoflurane and challenged intranasally with 2 MLD 50 of CA09. Following challenge, the mice were monitored twice daily for weight loss and survival until up to 14 days post-infection. Animals that lost 30% of their body weight (as a proportion of their initial weight) were euthanized by carbon dioxide in accordance with our animal protocols. For the immunogenicity experiment, BALB/c mice (female, 6-8 weeks old, n = 5 per group) were randomly separated into groups, anaesthetized and dosed with (intranasal or intravenous) PBS, mini-proteins (HB1.5702.3.3, HB1.6928.2.3, HB1.6394.2.3, HB36.6, Bot2110.4 or Bot3194.4), or monoclonal antibodies mIgG (Innovative IR-MSBC-GF) or hIgG (Innovative IR-HU-GF-ED). A total of three or four doses were administered two weeks apart for both the intranasal and intravenous doses. Blood was collected two weeks after each dose by retro orbital bleed using micro-haematocrit capillary tubes (Fisher). Serum was separated by centrifuging the blood samples in polymer gel chemistry tubes. For mouse experiments, researchers were not blinded to animal identity. ELISA. HB36.6, HB1.6928. Plates were blocked with 5% nonfat milk powder in PBS for 1 h at room temperature, and then washed three times with wash buffer (PBS-T; phosphate-buffered saline containing 0.05% Tween 20). Samples were diluted in a buffer containing 1% nonfat milk powder in PBS-T, added to the wells, and incubated for 1 hr at room temperature. Following three washes with PBS-T, plates were incubated with horseradish-peroxidase conjugated goat anti-mouse IgG (1/5,000 dilution) secondary antibodies (ThermoFisher 62-6520) for 1 h at room temperature. After five washes with PBS-T, TMB substrate (KPL 52-00-03) was added to the wells for 30 min at room temperature. Colour development was stopped by the addition of 50 μ l HCl (1 M), and the plates were read at 450 nm to measure relative optical densities. The average optical density of blank wells was subtracted to calculate the reported values. Statistical and power analyses. For animal studies, mice were randomly assigned to either treatment or control groups. In mouse influenza challenge studies, investigators were blinded to which treatment group each animal was assigned to during measurement of weight loss and survival. For all other analyses, investigators were not blinded to treatment groups or in the data analysis. A group size of n = 10 mice was determined based on power analysis, yielding 80% power to discern a difference of 5% weight-change between groups at an alpha value of 0.05, considering a standard deviation of 4% in weight-change at 4-7 days after infection. Survival analyses were performed using the Kaplan-Meier log-rank test. A P value of < 0.05 was considered to be significant. For mice, the minimum group size was determined using weight loss data with 70% of control mice becoming infected with CA09. Comparisons in antibody responses were performed using unpaired student t-test. With a standard deviation of 2% in weight loss, a group size of n = 5 yields > 80% power to detect a minimum of a 10% difference between groups in weight loss using a two-sided t-test with an alpha value of 0.05. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. Survival analyses were performed by using the Kaplan-Meier log-rank test. A P value of <0.05 was considered to be significant. For mice, the minimum group size was determined using weight loss data with 70% of control mice becoming infected with CA09. Comparisons in antibody responses were performed using unpaired student t-test. Based on a standard deviation of 2% in weight loss, a group size of n = 5 yields >80% power to detect a minimum of a 10% difference between groups in weight loss using a two-sided t-test with an alpha value of 0.
Data exclusions
Describe any data exclusions. None
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental finders were statistically significant and no attempt at reproduction was performed.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Female, 6-8 week-old BALB/c mice (female, 6-8 weeks old, n=5-10/group) were randomly separated into groups
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For mouse experiments, researchers were not blinded to animal identity.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
